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Dear Editor,
A 49-year-old Turkish male presented with intermit-
tent passage of dark-colored urine since 2007. Flow
cytometry demonstrated absence of CD55 and CD59
antigens, consistent with a diagnosis of paroxysmal
noc turna l hemoglobinur ia (PNH). He in i t ia l ly
responded to eculizumab, with improvement in anemia
and resolution of hemoglobinuria. In 2009, the patient
developed Coombs positive autoimmune hemolytic
anemia (AIHA), which responded to steroids. Since
he continued to require high doses of prednisone, sple-
n e c t omy was pe r f o rmed i n Novembe r 2009 .
Unfortunately, his AIHA persisted and he was treated
with four weekly doses of rituximab 375 mg/m2 in
June 2010. At that time, fluorescently labeled aerolysin
(FLAER) labeling on leukocytes failed to demonstrate
PNH, so treatment with eculizumab was discontinued.
In April 2014, the patient presented with septic shock
in the setting of asplenia. He developed acral ischemic
necrosis, requiring amputation of multiple fingers as
well as his left leg below the knee. With appropriate
resuscitation and antibiotic therapy, he was able to re-
cover and he eventually regained independence with
the aid of prosthesis. In February 2016, his complete
blood count showed white blood cells 15,170/mcL,
with 66 % lymphocytes, hemoglobin 9.2 g/dl, and
platelets 510,000/mcL. His peripheral blood smear re-
vealed a predominance of large granular lymphocytes
(LGL), which were CD8 and CD57 positive by flow
cytometry (Figs. 1 and 2). Additional studies revealed
clonal rearrangement of both beta and gamma T cell
receptor genes, as well as a CD4:CD8 ratio of 0.1. He
continues to require prednisone for AIHA.
Paroxysmal nocturnal hemoglobinuria (PNH) is an
acquired clonal disorder caused by somatic mutation
of the X-linked gene, PIG-A, which results in the de-
ficiency of glycosylphosphatidylinositol (GPI) [1].
Deficiency of specific GPI anchored proteins, CD55
and CD59, renders red cells exquisitely sensitive to
complement mediated destruction, leading to unabated
intravascular hemolysis [2]. Complement blockade
through the anti-C5 antibody, eculizumab, initially pre-
vents hemolysis. However, over a period of time, a
large number of C3 antigens accumulate [3]. C3 rich
red cells with abnormal GPI molecules sensitize the
immune system, resulting in T cell recognition and
opsonization by macrophages of the reticuloendothelial
system [4]. This phenomenon results in extravascular
hemolysis with Coombs positivity in PNH patients on
eculizumab [5]. Recent reports indicate that GPI-
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PNH patients, spare selectively GPI-negative stem
cells, thus enabling them to re-populate the marrow
of a patient who would otherwise have aplastic anemia
[6]. T cell receptor beta (TCR-beta) clones of the
CD8+ CD57+ T cell population are frequently de-
ranged in PNH, but not in healthy controls [7]. T cell
clones bearing a set of highly homologous TCR-beta
molecules in PNH suggest an immune process driven
by non-peptide antigen, as patients do not share iden-
tical HLA alleles. In PNH patients, the presence of
CD8 (+) T cells reactive against antigen-presenting
cells (APCs) loaded with GPI are seen in higher num-
bers than in healthy controls [8]. To our knowledge,
this is the first documented case of PNH with clonally
mutated large granular lymphocytic leukemia with beta
and gamma gene rearrangement, reported in the
literature.Fig. 1 Peripheral blood smear showing a large granular lymphocyte and
a Howell-Jolly body (status post splenectomy)
1748 Ann Hematol (2016) 95:1747–1749
Fig. 2 Flow cytometry demonstrating a lymphocyte population with expression of both CD8 and CD57
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